Results 131 to 140 of about 299,195 (309)
Global progress, challenges and strategies in eliminating public threat of viral hepatitis
Background The problem caused by viral hepatitis is a major public health challenge faced in the past decade, and the global goal of eliminating viral hepatitis by 2030 is still far away.
Sihui Zhang, Fuqiang Cui
doaj +1 more source
OBJECTIVE: To evaluate viral vaccine antibody levels in children with acute lymphoblastic leukemia after chemotherapy and after vaccine booster doses.
Simone Santana Viana +5 more
doaj +1 more source
Plant-based vaccines against viral hepatitis: A panoptic review
The traditional vaccines against hepatitis have been instrumental in reducing the incidence of some types of viral hepatitis; however, the need for cost-effective, easily distributable, and needle-free vaccine alternatives has led to the exploration of plant-based vaccines.
Reka, Devanathan +1 more
openaire +2 more sources
Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu +6 more
wiley +1 more source
Eliminating Viral Hepatitis from India and Southeast Asia by 2030: Challenges and Ways Forward
This review was conducted to understand the epidemiology of hepatitis in Southeast Asia, examine the current scenario, and suggest a way forward for elimination. A comprehensive desk review was followed by analysis and interpretation.
Senthilkumar Ramasamy +5 more
doaj +1 more source
Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection [PDF]
Chronic hepatitis B is still a major public health issue despite the successful prophylactic vaccination attempts. Chronicity of hepatitis B virus(HBV) is mainly due to its ability to debilitate host's immune system.
Faezeh Ghasemi +3 more
doaj
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias +8 more
wiley +1 more source
The Swiss Haemophilia Registry–Report From the First 8 Years
ABSTRACT Introduction Patient registries capture disease related information and provide a valuable source for real‐world data on rare diseases and their management. The Swiss Haemophilia Registry (SHR) was established in 2015 on the basis of a new Swiss federal human research act.
Alessandra Bosch +8 more
wiley +1 more source
Indoleamine 2,3‐dioxygenase (IDO) activity modulates immune responses to the therapeutic HBV vaccine NASVAC. Genetic or pharmacological suppression of IDO enhanced vaccine efficacy in mice, and lower serum kynurenine levels predicted favorable responses in humans, suggesting IDO as both a therapeutic target and a biomarker.
Yohei Shirakami +15 more
wiley +1 more source
Perspectives on Pertussis Prevention
Acta Paediatrica, EarlyView.
Ulrich Heininger
wiley +1 more source

